CLINICAL TRIALS PROFILE FOR AMPICILLIN AND SULBACTAM
✉ Email this page to a colleague
All Clinical Trials for AMPICILLIN AND SULBACTAM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00044746 ↗ | Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2000-10-01 | Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients. |
NCT00137007 ↗ | Zithromax EV in Community-Acquired Pneumonia (CAP) | Completed | Pfizer | Phase 4 | 2003-11-01 | The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide. This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy. |
NCT00356148 ↗ | The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. | Completed | Marmara University | Phase 4 | 2003-10-01 | This is a single center trial to compare the rate of surgical site infection (SSI) in normal (BMI equal to or less than 25; Control Group)) and overweight (BMI over 25) women who are undergoing breast cancer surgery. The overweight patients are further randomized into two groups; in one group patients receive prophylactic antibiotics (ampicillin/sulbactam; Prophylaxis Group), in the other they do not (No Prophylaxis Group). |
NCT00368537 ↗ | Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2006-09-01 | The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI). |
NCT00630513 ↗ | T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 4 | 2008-01-01 | The aim of the study was to compare the activity (efficacy and safety) of Ertapenem administered according to a short treatment for three days versus a short treatment for three days with AS in patients with an community acquired IAI of mild to moderate severity. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMPICILLIN AND SULBACTAM
Condition Name
Clinical Trial Locations for AMPICILLIN AND SULBACTAM
Trials by Country
Clinical Trial Progress for AMPICILLIN AND SULBACTAM
Clinical Trial Phase
Clinical Trial Sponsors for AMPICILLIN AND SULBACTAM
Sponsor Name